Focus on innovative ADC targets and indications driven by clinical relevancies, addressing unmet medical needs.
Integrating STAR-Lite bispecific antibody platform with Hy-BEAM ADC platform to enhance our capabilities on developing differentiated BsAb ADC products
Adopt scientific and methodical approach to drug development - based upon biology characteristics of target as well as translational research results
With high-level of expertise in CMC and rationally design of bispecific-linker-payload combinations, accounted for successful development and scaling of products.
● Not reduce the diversity of light chains (compared to common light chain animal platforms)
● Not rely on expensive mouse platforms such as Veloclmmune、OmniFlic、RenLite® 、 MeMo®
● Good CMC and developability, superior to nanobody and ScFv
● Similar CMC process to monoclonal antibodies,allowing scaling up
● Differentiated from DuoBody ®, STAR-Lite platform allows one-cell manufacturing
● Rational design based on biology, related to disease setting
● Site-specific conjugation yields homogeneous antibody-drug conjugates with defined drug-to-antibody ratios, enabling consistent therapeutic efficacy and improved safety profiles.
● Hydrophilic Linker, suitable for ADC development of high DAR, potentially enhancing the efficacy of the ADC.
● Greater therapeutic window in animal models, could be further improved/combined with other novel payloads
● Integrating STAR-Lite platform to avoid light chain mismatch, especially for BsAb ADCs ensuring better functionality of molecules with complex structure
● Good developability and excellent serum stability.
Bispecific ADC inhibit two signaling pathways simultaneously, potentially leading to synergistic effects in cancer treatment. By targeting multiple pathways to overcome drug resistance that often hampers traditional therapies typically focus on a single pathway.
Bispecific ADCs can specifically recognize and bind to tumor cells expressing two different target antigens simultaneously. The specificity spares normal cells that express only one of the antigens, potentially reducing off-target effects and increasing safety.
By binding two different epitopes on the same antigen molecule, a ternary complex is formed, which can enhance the rate of antigen internalization. This improved internalization rate promotes the efficacy of the ADC
Bispecific ADCs target tumor cells through avidity, which reduces the likelihood of affecting normal cells. The selective targeting improves the specificity and safety of drug, leading to an expanded therapeutic window.